Please note, this OEL/ADE monograph also applies to CAS RN 229614-55-5 and Peramivir trihydrate (CAS RN 1041434-82-5). Peramivir is an influenza virus neuraminidase inhibitor indicated for the treatment of acute uncomplicated influenza in patients 6 months old and older who have been symptomatic for no more than two days. The Food and Drug Administration (FDA) has authorized the emergency use of intravenous (IV) peramivir under emergency use authorization (EUA) in the United States (US) to treat adult and pediatric patients with suspected or laboratory-confirmed pandemic 2009 H1N1 influenza, or infection due to non-subtypable influenza A virus suspected to be 2009 H1N1 based on community epidemiology.
Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.
OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), as well as PIC/S and ANVISA requirements, and to obtain the following information:
To order an OEL/ADE monograph for Peramivir, just click the ADD TO CART button.
If you're wondering about HBEL, we have something for you.
Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.
Affygility Solutions’ OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.